These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 1229623)

  • 1. [Clinical aspects and therapy of plasmacytoma].
    Wilmanns W
    Verh Dtsch Ges Inn Med; 1975; 81():938-51. PubMed ID: 1229623
    [No Abstract]   [Full Text] [Related]  

  • 2. [Characteristics of drug resistance of tumor plasmocytes in vitro in patients with multiple myeloma differently responsive to chemotherapy].
    Golenkov AK; Trifonova EV; Kataeva EV; Kil'diushevskiĭ AV; Lutskaia TD; Zariad'eva EA; Nazarova IN; Lukashina MN; Zabotina TN; Mikhaĭlova IN; Inshakov AN; Logacheva NP; Baryshnikov AIu
    Ter Arkh; 2000; 72(8):38-41. PubMed ID: 11019426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Silent onset of multiple myeloma. How to diagnosis and when to treat?].
    Bartl R
    Internist (Berl); 1986 Mar; 27(3):192-200. PubMed ID: 3086250
    [No Abstract]   [Full Text] [Related]  

  • 4. Varied picture of multiple myeloma.
    Singh A; Singh TP; Datta AK
    J Indian Med Assoc; 1974 May; 62(10):348-51. PubMed ID: 4430839
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients.
    Mangiacavalli S; Pica G; Varettoni M; Lazzarino M; Corso A
    Eur J Haematol; 2009 Mar; 82(3):240-1. PubMed ID: 19018860
    [No Abstract]   [Full Text] [Related]  

  • 6. [Differential diagnosis and therapy of plasmocytoma of the head and neck (author's transl)].
    Löbe LP; Katenkamp D
    Laryngol Rhinol Otol (Stuttg); 1982 Jul; 61(7):388-91. PubMed ID: 7109802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MOPC-315 murine plasmacytoma as a model anticancer screen for human multiple myeloma.
    Valeriote F; Grates H
    J Natl Cancer Inst; 1986 Jan; 76(1):61-5. PubMed ID: 3455743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hemocytological classification, clinical staging and polychemotherapy of multiple myeloma].
    István L; Karl W; Michael H; Günter A; Kelényi G; Várbíró M; Dieter R
    Orv Hetil; 1983 Feb; 124(6):313-9. PubMed ID: 6835675
    [No Abstract]   [Full Text] [Related]  

  • 9. Advances in the diagnosis and management of myeloma.
    Greipp PR
    Semin Hematol; 1992 Jul; 29(3 Suppl 2):24-45. PubMed ID: 1509293
    [No Abstract]   [Full Text] [Related]  

  • 10. Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon.
    Ali R; Ozkalemkas F; Ozkan A; Ozkocaman V; Ozcelik T; Ozan U; Kurt M; Tunali A
    Leuk Res; 2007 Aug; 31(8):1153-5. PubMed ID: 16945413
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of aniline mustard in patients with multiple myeloma.
    Kyle RA; Costa G; Cooper MR; Ogawa M; Silver RT; Glidewell O; Holland JF
    Cancer Res; 1973 May; 33(5):956-60. PubMed ID: 4703127
    [No Abstract]   [Full Text] [Related]  

  • 12. The therapy of myeloma. A conceptual approach.
    Jacobs P; Dubovsky D
    Cent Afr J Med; 1975 Jul; 21(7):158-60. PubMed ID: 1182791
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical study on chemotherapy for multiple myeloma. Part III: The disappearance of M-protein in multiple myeloma].
    Adachi T; Hasegawa M; Asano K; Sezaki T; Ishii H; Takahashi I; Kimura I
    Rinsho Ketsueki; 1983 Apr; 24(4):440-7. PubMed ID: 6887544
    [No Abstract]   [Full Text] [Related]  

  • 14. Pseudo-Gaucher cells in multiple myeloma.
    Shenjere P; Roy A; Eyden B; Banerjee SS
    Int J Surg Pathol; 2008 Apr; 16(2):176-9. PubMed ID: 18417675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma.
    Rajkumar SV; Richardson PG; Lacy MQ; Dispenzieri A; Greipp PR; Witzig TE; Schlossman R; Sidor CF; Anderson KC; Gertz MA
    Clin Cancer Res; 2007 Oct; 13(20):6162-7. PubMed ID: 17947482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma.
    Galli M; Elice F; Crippa C; Comotti B; Rodeghiero F; Barbui T
    Haematologica; 2004 Sep; 89(9):1141-2. PubMed ID: 15377478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative evaluation of the effectiveness of mono- and polychemotherapy programs in patients with multiple myeloma].
    Abdulkadyrov KM; Bessmel'tsev SS
    Klin Med (Mosk); 1992; 70(9-10):57-60. PubMed ID: 1474818
    [No Abstract]   [Full Text] [Related]  

  • 18. [Biological and clinical significance of plasma-cell acid phosphatase in multiple myeloma].
    Musto P; Barbieri D; Gennari M; Spanedda R; Scapoli G; Carotenuto M; Castoldi G
    Recenti Prog Med; 1986 Oct; 77(10):452-60. PubMed ID: 3823590
    [No Abstract]   [Full Text] [Related]  

  • 19. New horizons in multiple myeloma therapy.
    Santos ES; Kharfan-Dabaja MA
    Expert Rev Anticancer Ther; 2006 Oct; 6(10):1483-501. PubMed ID: 17069532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognosis of multiple myeloma].
    Morell A; Skvaril F; Rüst HP; Spengler GA; Brunner K; Barandun S
    Schweiz Med Wochenschr; 1970 Nov; 100(46):1990-2. PubMed ID: 5507847
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.